Biomarin Pharmaceutical (BMRN) Receivables (2016 - 2025)
Historic Receivables for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $790.3 million.
- Biomarin Pharmaceutical's Receivables rose 163.58% to $790.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $790.3 million, marking a year-over-year increase of 163.58%. This contributed to the annual value of $660.5 million for FY2024, which is 423.4% up from last year.
- Latest data reveals that Biomarin Pharmaceutical reported Receivables of $790.3 million as of Q3 2025, which was up 163.58% from $855.9 million recorded in Q2 2025.
- Biomarin Pharmaceutical's 5-year Receivables high stood at $855.9 million for Q2 2025, and its period low was $373.4 million during Q4 2021.
- In the last 5 years, Biomarin Pharmaceutical's Receivables had a median value of $597.9 million in 2023 and averaged $574.3 million.
- Per our database at Business Quant, Biomarin Pharmaceutical's Receivables crashed by 1671.73% in 2021 and then skyrocketed by 3900.2% in 2023.
- Quarter analysis of 5 years shows Biomarin Pharmaceutical's Receivables stood at $373.4 million in 2021, then rose by 23.55% to $461.3 million in 2022, then skyrocketed by 37.37% to $633.7 million in 2023, then grew by 4.23% to $660.5 million in 2024, then rose by 19.64% to $790.3 million in 2025.
- Its last three reported values are $790.3 million in Q3 2025, $855.9 million for Q2 2025, and $739.2 million during Q1 2025.